Zyprexa Tablets 5 mg (Olanzapine)

Adult dose

The therapeutic dose of this drug should be adjusted according to the patient's clinical condition. Dose increases beyond the usual recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. 1. Adults 1) Schizophrenia (1) The recommended initial dose is 5∼10 mg of olanzapine once daily. (2) Maintenance treatment: Although it is difficult to give a definitive answer as to how long treatment with this drug should continue, its efficacy was demonstrated in a placebo-controlled study in which patients with schizophrenia whose symptoms had stabilized after taking this drug for approximately 8 weeks received maintenance treatment at doses of 10∼20 mg daily for 8 months. The need for maintenance treatment at an appropriate dose should be assessed periodically. 2) Bipolar disorder (1) Treatment of manic or mixed episodes associated with bipolar I disorder The initial dose is 15 mg of this drug once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. (2) Prevention of recurrence in bipolar disorder The recommended initial dose is 10 mg once daily. Patients who have been receiving this drug to treat mania should continue the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, treatment with this drug should continue along with adjunctive therapy to treat mood symptoms, according to clinical indications (optimizing the required doses). 3) For schizophrenia, treatment of manic and mixed episodes associated with bipolar I disorder, and prevention of recurrence in bipolar disorder, the daily dose may be adjusted within the range of 5 mg to 20 mg daily based on the clinical condition. Doses above the recommended initial dose are recommended only after an appropriate clinical evaluation and should generally be increased at intervals of at least 24 hours. If treatment with this drug is discontinued, the dose should be reduced gradually and cautiously. 4) Acute treatment of depressive episodes associated with bipolar I disorder Start treatment with 5 mg of olanzapine once daily, and increase to 10 mg once daily. Administer this drug at bedtime and adjust the dose as appropriate according to age and symptoms; do not exceed a daily dose of 20 mg. This drug may be administered without regard to meals because food does not affect its absorption. 2. Administration in special populations 1) Elderly patients Starting at a dose of 5 mg or less daily may be considered when there is sufficient evidence of clinical factors supporting this approach. 2) Patients with renal or hepatic impairment A low initial dose (5 mg) should be considered. In moderate hepatic impairment (cirrhosis, Child-Pugh class A or B), the initial dose is 5 mg and should be increased cautiously. 3) Patients with multiple factors that delay the metabolism of this drug (female sex, advanced age, and nonsmoking status) may also be started at a low dose.

This medication can cause a very serious and potentially life-threatening side effect known as neuroleptic malignant syndrome, so if symptoms such as high fever or muscle rigidity occur, usage should be discontinued immediately and consultation with a doctor should be sought. It is advisable not to use this drug for the treatment of dementia-related psychosis or behavioral disturbances, especially in elderly patients as there is an increased risk of mortality and cerebrovascular disorders. Long-term use may result in tardive dyskinesia, which is an involuntary movement disorder, so if abnormal symptoms appear, dose adjustments or discontinuation should be considered. During the use of this medication, regular monitoring of blood glucose, weight, and lipid levels is necessary to manage the risk of diabetes or cardiovascular diseases. Drowsiness or dizziness may occur at the beginning of treatment, so it is safer to avoid driving or operating hazardous machinery. Patients with poor liver function or liver disease should regularly undergo liver function tests and discontinue if symptoms of hepatitis occur. This drug should be administered cautiously to pregnant or breastfeeding women, especially in the third trimester of pregnancy, as newborns may exhibit withdrawal symptoms or movement disorders. In case of overdose, symptoms such as decreased consciousness, cardiac issues, seizures, etc., may occur, requiring immediate emergency treatment, and since there is no specific antidote, treatment according to symptoms is necessary. When co-administered with other medications, possible interactions may occur, hence appropriate dose adjustments and monitoring should be discussed with a doctor or pharmacist. The safety and efficacy of this drug have not been sufficiently confirmed in children and adolescents, so it should be used with caution.

• High fever
• muscle rigidity
• changes in mental state
• irregular pulse
• changes in blood pressure
• tachycardia
• sweating
• cardiac arrhythmia
• elevated creatine phosphokinase
• myoglobinuria

Store this medication in a tightly closed container to prevent air and moisture from entering, and it is advisable to keep it at room temperature, between 15 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a long time.

Appearance

Film-coated white round tablets

Package unit

28 tablets (7 tablets/PTPX4) / carton